Recently, Professor REN Guosheng’s team and Professor LI Hongzhong’s team from the First Affiliated Hospital of Chongqing Medical University, along with Professor WAN Jingyuan’s team from the College of Pharmacy of CQMU, have published a research paper titled “Insulin-like Growth Factor 2 Drives Fibroblast-mediated Tumor Immunoevasion and Confers Resistance to Immunotherapy” in the internationally renowned Journal of Clinical Investigation.
This study found that Insulin-like Growth Factor 2 (IGF2) derived from Cancer-associated Fibroblasts (CAFs) serves as a crucial upstream molecule. It can establish physical and chemical barriers by regulating the cancer-promoting functions of CAFs, thereby inhibiting the infiltration and anti-tumor activity of CD8+ T cells. This process facilitates tumor immune evasion and resistance to immunotherapy, providing potential molecular markers and therapeutic targets for tumor diagnosis and treatment.
Link to full article: https://www.jci.org/articles/view/183366
